Processing, please wait...
7 videos 1 badge
Premium

Dr Michael BENZAQUEN

Dermatologist
Switzerland

I completed medical education at the Faculty of Medicine of Marseille, Aix-Marseille University (Marseille, France), and ranked first among 3000 students in the first year of medical school. I then completed my residency in Dermatology at Assistance Publique Hôpitaux de Marseille, before a fellowship in the department of Dermatology at Hôpital Nord de Marseille. My professional experiences abroad in Columbia University (New York City, USA) and Inselspital - University Hospital of Bern (Bern, Switzerland) improved my clinical skills and knowledge in Dermatology, as well as my success in ECFMG certification (USA). I graduated from several inter-university diplomas in Internal Medicine, Pediatric Dermatology, Dermatological Laser and Dermatological Surgery. My works have been published in international peer-reviewed journals and I am regularly invited as speaker in international congresses. I investigated in various fields, ranging from infectious and inflammatory diseases to onco-dermatology, laser and surgery. As the Vice-President of the Scientific Council of the French Laser Group, I encouraged young dermatologists in learning and practicing dermatological lasers. I am currently working as clinical chief in the department of dermatology of Inselspital-University Hospital of Bern, Switzerland.

read more
add item add Michael BENZAQUEN

Michael BENZAQUEN's lectures (7)

Michael BENZAQUEN's publications (31)

Laser-Assisted Hyaluronic Acid Delivery by Fractional Carbon Dioxide Laser in Facial Skin Remodeling: A Prospective Randomized Split-Face Study in France.

Apr, 2021

Combining the efficacy of ablative fractional carbon dioxide lasers (AFXL) to laser-assisted hyaluronic acid delivery (LAHAD) has not yet been studied. The objective of our study was to evaluate the safety and the efficacy of laser-assisted hyaluronic acid (HA) delivery with AFXL in facial skin remodeling. read more

Lasers in surgery and medicine

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.

Mar, 2021

Immune checkpoint inhibitors (ICI), most commonly anti-PD-1 (programmed cell death 1) and anti-PD-L1 (programmed cell death ligand 1) therapies, have revolutionized the treatment of many cancers. ICI may activate the immune system response even in healthy tissues, which can cause immune-related adverse events (irAEs).(1) Several cases of bullous pemphigoid (BP) triggered by anti-PD-1/PD-L1 therapy have been reported. read more

Journal of the European Academy of Dermatology and Venereology : JEADV

Herpetiform aphthous ulcerations induced by secukinumab: Report of 2 cases.

Oct, 2020

read more

JAAD case reports
Load more  

Michael BENZAQUEN's scientific societies (5)